[
  {
    "ts": null,
    "headline": "Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit",
    "summary": "Entrada Therapeutics (NASDAQ:TRDA) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to outline its pipeline focus on intracellular therapeutics and to preview multiple clinical data catalysts expected in 2026, particularly in Duchenne muscular dystrophy (DMD) and myotonic dys",
    "url": "https://finnhub.io/api/news?id=b05c2c32b4ec17bace8f180d7bb014982e36b7148e1efad0fe96ee2d4aa0c076",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771185771,
      "headline": "Entrada Therapeutics Teases Data-Rich 2026 With DMD and DM1 Catalysts at Guggenheim Summit",
      "id": 139108318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Entrada Therapeutics (NASDAQ:TRDA) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to outline its pipeline focus on intracellular therapeutics and to preview multiple clinical data catalysts expected in 2026, particularly in Duchenne muscular dystrophy (DMD) and myotonic dys",
      "url": "https://finnhub.io/api/news?id=b05c2c32b4ec17bace8f180d7bb014982e36b7148e1efad0fe96ee2d4aa0c076"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story",
    "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) has signed a license and research agreement with WuXi Biologics for a trispecific T cell engager targeting B cell mediated autoimmune diseases. The deal gives Vertex exclusive global rights to a preclinical stage asset, expanding its pipeline beyond cystic fibrosis. The partnership focuses on autoimmune conditions where existing treatment options leave substantial unmet medical need. For investors watching Vertex at a share price of $491.47, this move...",
    "url": "https://finnhub.io/api/news?id=64b01d041be9445d52630b3bdee86601f8e4414dd174e1f654631d6ae25c8f38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771135742,
      "headline": "Vertex Autoimmune Deal With WuXi Adds New Angle To VRTX Valuation Story",
      "id": 139104728,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) has signed a license and research agreement with WuXi Biologics for a trispecific T cell engager targeting B cell mediated autoimmune diseases. The deal gives Vertex exclusive global rights to a preclinical stage asset, expanding its pipeline beyond cystic fibrosis. The partnership focuses on autoimmune conditions where existing treatment options leave substantial unmet medical need. For investors watching Vertex at a share price of $491.47, this move...",
      "url": "https://finnhub.io/api/news?id=64b01d041be9445d52630b3bdee86601f8e4414dd174e1f654631d6ae25c8f38"
    }
  },
  {
    "ts": null,
    "headline": "CRISPR Therapeutics Advances Casgevy Rollout As Pipeline And Valuation Attract Attention",
    "summary": "CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing therapy for sickle cell disease. Reimbursement and access for Casgevy now extend to the majority of eligible patients in the U.S., with rollouts reaching Europe and the Middle East. The company highlights new pipeline moves in autoimmune diseases, oncology, and lipid disorders, supported by collaborations with Vertex Pharmaceuticals and Sirius Therapeutics. For you...",
    "url": "https://finnhub.io/api/news?id=536b77543b1c436c986279bcf94b70629793833c018b504c128409d66e557efb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771114955,
      "headline": "CRISPR Therapeutics Advances Casgevy Rollout As Pipeline And Valuation Attract Attention",
      "id": 139103252,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing therapy for sickle cell disease. Reimbursement and access for Casgevy now extend to the majority of eligible patients in the U.S., with rollouts reaching Europe and the Middle East. The company highlights new pipeline moves in autoimmune diseases, oncology, and lipid disorders, supported by collaborations with Vertex Pharmaceuticals and Sirius Therapeutics. For you...",
      "url": "https://finnhub.io/api/news?id=536b77543b1c436c986279bcf94b70629793833c018b504c128409d66e557efb"
    }
  }
]